

Patent Claims:

1. A pharmaceutical composition comprising a first and a second antibody molecule, or a portion thereof, having the capability to bind to different epitopes located on same or different ErbB receptor molecule types, wherein said first antibody molecule or a portion thereof, comprises binding sites that bind to a first specific epitope on the ErbB1 receptor molecule type, and said second antibody molecule comprises binding sites that bind to a second specific epitope on the same ErbB1 receptor molecule type.
2. A pharmaceutical composition according to claim 1 or 2, wherein at least said first or said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
3. A pharmaceutical composition according to claim 1, wherein said first and said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
4. A pharmaceutical composition according to claim 2 or 3, wherein said receptor binding domain is the binding domain of the natural ligand of said ErbB1 receptor molecule type.
5. A pharmaceutical composition according to claim 2 or 3, wherein the first and second antibody, or fragment thereof, binds to different epitopes within the binding domain of the natural ligand(s) of said ErbB1 receptor molecule type.
6. A pharmaceutical composition according claims 5, wherein blocking and / or inhibition of the ErbB receptor, and induction of down-regulation of ErbB receptor-specific pathway signaling is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
7. A pharmaceutical composition according to any of the claims 1 to 6, wherein the induction of cross-linking and / or dimerization of ErbB receptor molecules of the

same or different specificity is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.

- 5 8. A pharmaceutical composition of claim 7, wherein said ErbB receptor molecules, are involved in cross-linking and / or dimerization, and are selected from ErbB1 and ErbB2 (Her-2).
- 10 9. A pharmaceutical composition according to any of the claims 1 – 8, wherein said first and / or said second antibodies is a monospecific antibody.
- 15 10. A pharmaceutical composition according to any of the claims 1 to 9, wherein the first antibody is murine, chimeric or humanized MAb 425.
- 20 11. A pharmaceutical composition according to any of the claims 1 to 9, wherein the second antibody is murine, chimeric or humanized MAb 225.
- 25 12. A pharmaceutical composition according to claim 10 or 11, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).
- 30 13. A pharmaceutical composition according to any of the claims 1 to 12, comprising additionally a cytotoxic agent.
14. A pharmaceutical composition according to claim 13, wherein said cytotoxic agent is a chemotherapeutic agent.
15. A pharmaceutical composition according of claim 14, wherein said chemotherapeutic agent is selected from any of the compounds of the group:
cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
16. A pharmaceutical composition of claim 15, wherein said cytotoxic agent is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.

17. A pharmaceutical composition according to any of the claims 1 to 12, wherein said first and / or said second antibody molecule is an immunoconjugate, wherein the antibody portion is fused by its C-terminus to a biologically effective peptide, polypeptide or protein, optionally via a linker peptide.
- 5
18. A pharmaceutical composition of claim 17, wherein the protein is a cytokine.
19. A pharmaceutical kit comprising
- (i) a first package comprising a first antibody molecule, or a portion thereof,
- 10 which comprises binding sites that bind to a first specific epitope present on a ErbB1 receptor molecule, and
- (ii) a second package comprising a second antibody molecule which comprises binding sites that bind to a second different specific epitope on the same ErbB1 receptor molecule type.
- 15
20. A pharmaceutical kit according to claim 19, wherein at least said first or said second eptitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
- 20
21. A pharmaceutical kit according to claim 19, wherein said first and said second eptitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
22. A pharmaceutical kit according to any of the claims 19 to 21, wherein at least one
- 25 of said molecules binds to an epitope within the ErbB1 receptor binding domain to which the natural ligand of the receptor binds.
23. A pharmaceutical kit according to any of the claims 19 – 22, wherein said first antibody molecule is murine, chimeric or humanized monoclonal antibody 425,
- 30 and said second molecule is murine, chimeric or humanized monoclonal antibody 225.

24. A pharmaceutical kit according to claim 23 comprising a first package that comprises humanized MAb 425 (h425) and a second package that comprises chimeric MAb 225 (c225).
- 5 25. A pharmaceutical kit according to any of the claims 19 – 24 comprising additionally a third package comprising a cytotoxic agent.
26. A pharmaceutical kit according to claim 25, wherein said cytotoxic agent is a chemotherapeutic agent.
- 10 27. A pharmaceutical kit according to claim 26, wherein said chemotherapeutic agent is selected from any of the compounds of the group: cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
- 15 28. A pharmaceutical kit according claim 26, wherein said cytotoxic drug is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.
- 20 29. Use of a pharmaceutical composition or a pharmaceutical kit as defined in any of the claims 1 – 28, for the manufacture of a medicament to treat tumors or tumor related diseases.